Moreover, the evidence that BTK is also expressed on many hematopoietic cells suggests that the huge success of the BTK inhibitors in CLL also appears to be related to its pleiotropic activity on cells of the tumor microenvironment [81,82,83]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.